Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jul 15;17(7):4867-4878.
doi: 10.62347/GOXN1938. eCollection 2025.

Rituximab plus chemotherapy for pediatric mature B-cell non-Hodgkin's lymphoma: a systematic review and meta-analysis

Xiuli Zhu  1 , Yuqiao Diao  1 , Yan Chen  1
Affiliations
Review

Rituximab plus chemotherapy for pediatric mature B-cell non-Hodgkin's lymphoma: a systematic review and meta-analysis

Xiuli Zhu et al. Am J Transl Res. .

Abstract

Objective: To conduct a systematic review and meta-analysis evaluating the efficacy and safety of rituximab combined with chemotherapy for the treatment of mature B-cell non-Hodgkin's lymphoma (NHL) in children and adolescents.

Methods: A comprehensive search of PubMed, Embase, the Cochrane Library, and Web of Science was performed to identify relevant studies published up to October 2024. Eligible studies included those involving patients aged 0-15 years diagnosed with mature B-cell NHL. Data were extracted on event-free survival (EFS), overall survival (OS), complete remission rate (CRR), adverse events, immune reconstitution (IgG levels), and recurrence rates. Meta-analyses were conducted using RevMan 5.0.

Results: A total of 11 studies comprising 1,522 participants were included. The addition of rituximab to chemotherapy significantly improved EFS (hazard ratio [HR] = 0.40, 95% confidence interval [CI]: 0.36-0.45, P < 0.05) and OS (HR = 0.38, 95% CI: 0.34-0.42, P < 0.05). CRR was also significantly higher in the rituximab group (odds ratio [OR] = 2.72, 95% CI: 1.76-4.21, P < 0.05). However, a higher incidence of adverse effects was observed (OR = OR= 1.92, 95% CI: 1.25-2.94, P < 0.05). There were no significant differences in recurrence rate or IgG levels between groups.

Conclusion: The addition of rituximab to chemotherapy significantly improved EFS, OS, and CRR in children and adolescents with mature B-cell NHL. Despite an increased risk of toxicity, the survival and remission benefits support the use of rituximab in this population.

Keywords: Rituximab treatment; chemotherapy regime; children and adolescents; effectiveness and safety; mature B-cell non-Hodgkin’s lymphoma.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

Figure 1
Figure 1
Literature searching diagram.
Figure 2
Figure 2
Risk of bias.
Figure 3
Figure 3
Forest plot showing the event-free survival rates.
Figure 4
Figure 4
Forest plot showing the overall survival rates.
Figure 5
Figure 5
Forest plot showing the complete remission rates.
Figure 6
Figure 6
Forest plot showing the incidence of toxic effects.
Figure 7
Figure 7
Forest plot showing the immune reconstitution results.
Figure 8
Figure 8
Forest plot showing recurrence rates.
Figure 9
Figure 9
Funnel plots. (A) Event-free survival; (B) Overall survival; (C) Complete remission rate; (D) Toxic effects; (E) Immune reconstitution; (F) Recurrence rate.
See this image and copyright information in PMC

References

    1. Sapkota S, Shaikh H. Non-Hodgkin Lymphoma. StatPearls. Treasure Island (FL) ineligible companies. Disclosure: Hira Shaikh declares no relevant financial relationships with ineligible companies.: StatPearls Publishing Copyright © 2025, StatPearls Publishing LLC.; 2025.
    1. Alexander S, Aupérin A, Bomken S, Csóka M, Kazanowska B, Chiang AK, Andres M, Uyttebroeck A, Burke GAA, Zsiros J, Pillon M, Bollard CM, Mussolin L, Verdu-Amoros J, Neven B, Barkauskas DA, Wheatley K, Patte C, Gross TG, Minard-Colin V Children’s Oncology Group; European Intergroup for Childhood Non-Hodgkin’s Lymphoma. Effect of rituximab on immune status in children with mature B-cell non-Hodgkin lymphoma: a prespecified secondary analysis of the Inter-B-NHL Ritux 2010 trial. Lancet Haematol. 2023;10:e445–e457. - PMC - PubMed
    1. Burke GAA, Vinti L, Kabickova E, Beishuizen A, Tacyildiz N, Uyttebroeck A, Kang HJ, Luisi F, Minard-Colin V, Burkhardt B, Tamegnon M, Sun S, Curtis M, Deshpande S, Nottage K, Howes A, Srinivasan S, Bhojwani D, Norris R, Cairo M. Ibrutinib plus RICE or RVICI for relapsed/refractory mature B-cell non-Hodgkin lymphoma in children and young adults: SPARKLE trial. Blood Adv. 2023;7:602–610. - PMC - PubMed
    1. Falchi L, Vardhana SA, Salles GA. Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities. Blood. 2023;141:467–480. - PMC - PubMed
    1. Bethke M, Varga G, Weinhage T, Sabharwal H, Mellgren K, Randau G, Rolfing M, Wittkowski H, Foell D, Michgehl U, Burkhardt B. Patient parameters and response after administration of rituximab in pediatric mature B-cell non-Hodgkin lymphoma. Pediatr Blood Cancer. 2022;69:e29514. - PubMed

LinkOut - more resources